Jianghong Fan

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Drug Administration

Small Cell Lung Cancer

Tyrosine Kinase

Myasthenia Gravis

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller, Lili Pan, Jeanne F Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E Dorff, Anup K Amatya, Pallavi S Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K Leighton, Nam Atiqur Rahman, Richard Pazdur, Harpreet Singh, Paul G Kluetz, Nicole Drezner
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller, Lili Pan, Jeanne F Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E Dorff, Anup K Amatya, Pallavi S Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K Leighton, Nam Atiqur Rahman, Richard Pazdur, Harpreet Singh, Paul G Kluetz, Nicole Drezner
FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller, Lili Pan, Jeanne F Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E Dorff, Anup K Amatya, Pallavi S Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K Leighton, Nam Atiqur Rahman, Richard Pazdur, Harpreet Singh, Paul G Kluetz, Nicole Drezner
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller, Lili Pan, Jeanne F Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E Dorff, Anup K Amatya, Pallavi S Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K Leighton, Nam Atiqur Rahman, Richard Pazdur, Harpreet Singh, Paul G Kluetz, Nicole Drezner
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Shruti U Gandhy, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Sriram Subramaniam, Hong Zhao, Miao Zhao, Youwei Bi, Guansheng Liu, Jianghong Fan, Oluseyi Adeniyi, Rosane Charlab, Dubravka Kufrin, Matthew D Thompson, Kristin Jarrell, Doris Auth, Steven J Lemery, Richard Pazdur, Paul G Kluetz, Lola A Fashoyin-Aje
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Fang Wu, Youssef Mousa, Kimberly Raines, Chris Bode, Yu Chung Tsang, Rodrigo Cristofoletti, Hongling Zhang, Tycho Heimbach, Lanyan Fang, Filippos Kesisoglou, Amitava Mitra, James E Polli, Myong-Jin Kim, Jianghong Fan, Banu S Zolnik, Duxin Sun, Yi Zhang, Liang Zhao
Regulatory Utility of Physiologically Based Pharmacokinetic Modeling to Support Alternative Bioequivalence Approaches and Risk Assessment: A Workshop Summary Report. CPT: pharmacometrics & systems pharmacology (2022)